Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of Lonitoclax + Azacitidine (Aza) in Acute Myeloid Leukemia (AML) Patients

NCT07303660 is registered in ClinicalTrials.gov with Lomond Therapeutics Holdings, Inc. as lead sponsor.

NCT NCT07303660
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07303660 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of Lonitoclax + Azacitidine (Aza) in Acute Myeloid Leukemia (AML) Patients
Lead sponsor
Lomond Therapeutics Holdings, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
November 14, 2025
Completion date
July 31, 2027
Enrollment
66 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia